Accurate evaluation model of burning mouth syndrome based on inflammatory factors and psychological scores: a clinical study
10.3760/cma.j.cn112144-20241211-00469
- VernacularTitle:基于炎症因子和心理评分的灼口综合征临床评估模型初探
- Author:
Ying ZHANG
1
;
Sai YE
;
Hong SUN
;
Xuemin SHEN
;
Lan WU
Author Information
1. 上海交通大学医学院附属第九人民医院口腔黏膜病科 上海交通大学口腔医学院 国家口腔医学中心 国家口腔疾病临床医学研究中心 上海市口腔医学重点实验室 上海市口腔医学研究所，上海 200011
- Publication Type:Journal Article
- Keywords:
Mouth mucosa;
Burning mouth syndrome;
Clinical evaluation model;
Anxiety;
Depression;
Inflammatory factors
- From:
Chinese Journal of Stomatology
2025;60(3):232-238
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the correlation between anxiety, depression, and inflammatory markers in the body fluids of patients with burning mouth syndrome (BMS), creating a preliminary assessment model based on clinical data.Methods:Forty-one BMS patients were recruited according to the predefined inclusion criteria and exclusion criteria from the Department of Oral Medicine, Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine between December 2021 and September 2023, along with 12 healthy controls. The pain intensity of the 41 patients was assessed using the visual analog scale (VAS). Meanwhile, anxiety and depression were assessed using the Zung self-rating anxiety scale (SAS) and the Zung self-rating depression scale (SDS). The concentrations of brain-derived neurotrophic factor (BDNF), interferon-γ (IFN-γ), interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor-alpha (TNF-α) in saliva and serum were measured using the Luminex 200 TM system and enzyme-linked immunosorbent assay. Statistical analyses were performed using the Chi-square test, independent samples t-test, ANOVA, Spearman′s correlation analysis, and multiple linear regression, respectively. Results:The VAS score for the 41 BMS patients was (3.56±1.90), with 48.8% (20/41) and 41.5% (17/41) of patients experiencing mild and moderate pain, respectively. Only 7.3% (3/41) of patients had severe pain. Among the 41 BMS patients, 61.0% (25/41) exhibited anxiety and/or depression, in whom 39.0% (16/41) had both anxiety and depression, 9.8% (4/41) experienced anxiety without depression, and 12.2% (5/41) had depression without anxiety. The concentrations of IFN-γ and TNF-α in the serum and saliva of BMS patients were significantly higher than those in healthy controls (all P<0.05). In contrast, the BDNF concentration in serum was significantly lower in BMS patients than in healthy participants ( P<0.01), but was significantly higher in saliva ( P<0.001). Serum TNF-α was positively correlated with IFN-γ, IL-1β, and IL-6 (β=0.803, β=0.812, β=0.592; all P<0.01), while saliva TNF-α was negatively correlated with both anxiety and depression (β=-0.325, β=-0.321; all P<0.05). SAS scores were linearly correlated with saliva TNF-α concentrations (SAS=51.374-1.154×saliva TNF-α); saliva TNF-α concentrations were linearly correlated with saliva IFN-γ and IL-1β (saliva TNF-α=2.408+0.281×saliva IFN-γ+0.002×saliva IL-1β). Conclusions:This study provides a preliminary exploration of a clinical assessment model for BMS based on inflammatory markers and psychological scores, offering an exploratory framework for further research and optimization of the model.
